CervoMed Inc. (CRVO)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $25.57M
Last updated: Nov 17, 2026 at 11:04 AM ET
CervoMed Inc. (CRVO) Financials: Revenue, Profit and Cash Flow
CervoMed reported revenue of $4.01M for the fiscal year ended Dec 31, 2025, down 58.9% from the year before. That year, net income was -$26.97M with a net margin of -673.1%, operating cash flow was -$23.45M and free cash flow was -$23.45M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$5.90M.
Revenue and Margins
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $4.01M | -58.9% | 100.0% | -706.2% | -673.1% |
| Dec 2024 | $9.74M | +36.3% | 100.0% | -187.2% | -167.3% |
| Dec 2023 | $7.14M | N/A | 100.0% | -109.3% | -30.4% |
| Dec 2022 | $0 | N/A | N/A | N/A | N/A |
| Dec 2021 | $0 | N/A | N/A | N/A | N/A |
| Dec 2020 | $0 | N/A | N/A | N/A | N/A |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | N/A | N/A | N/A | N/A |
| Dec 2017 | $0 | N/A | N/A | N/A | N/A |
| Dec 2016 | $0 | N/A | N/A | N/A | N/A |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.01M | $9.74M | $7.14M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | $4.01M | $9.74M | $7.14M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development | $21.82M | $18.80M | $8.44M | $1.34M | $8.50M | $9.43M | $6.62M | $5.75M | $5.09M | $7.25M |
| Operating income | -$28.29M | -$18.23M | -$7.81M | -$3.48M | -$24.68M | -$15.97M | -$11.55M | -$18.96M | -$11.35M | -$18.37M |
| Net income | -$26.97M | -$16.29M | -$2.17M | -$5.80M | -$24.10M | -$14.19M | -$11.80M | -$18.37M | -$1.36M | -$18.04M |
| EBITDA | N/A | N/A | -$2.39M | N/A | -$24.58M | -$15.87M | -$11.45M | -$18.85M | -$2.27M | -$18.31M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $8.73K | $322.57K | $1.76M | $1.92M | $2.16M | $1.94M | $3.29M | $2.35M | $2.49M |
| Gross profit | $0 | $0 | $0 | $8.73K | $322.57K | $1.76M | $1.92M | $2.16M | $1.94M | $3.29M | $2.35M | $2.49M |
| Operating income | -$6.10M | -$6.68M | -$8.11M | -$8.33M | -$8.04M | -$6.62M | -$5.30M | -$7.24M | -$5.40M | -$3.00M | -$2.59M | -$2.48M |
| Net income | -$5.90M | -$6.57M | -$7.96M | -$8.09M | -$7.73M | -$6.26M | -$4.89M | -$6.71M | -$4.75M | -$2.32M | -$2.51M | -$2.36M |
Balance Sheet
As of Dec 2025, cash and equivalents of $8.24M were 36.0% of total assets of $22.88M, against total liabilities of $4.66M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $22.88M | $43.08M | $9.97M | $4.16M | $37.84M | $27.73M | $24.11M | $18.20M | $26.15M | $17.48M |
| Current assets | $22.88M | $43.08M | $9.96M | $4.16M | $37.82M | $18.78M | $14.65M | $8.91M | $9.67M | $1.60M |
| Cash and equivalents | $8.24M | $9.00M | $7.79M | $4.09M | $37.31M | $18.52M | $14.18M | $7.99M | $8.90M | $1.55M |
| Total liabilities | $4.66M | $3.88M | $2.60M | $13.16M | $2.93M | $2.92M | $3.98M | $2.59M | $4.92M | $8.30M |
| Short-term debt | N/A | N/A | N/A | $12.41M | $4.11M | $113.47K | $111.48K | N/A | $550.00K | $1.88M |
| Long-term debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $550.00K |
| Shareholder equity | $18.22M | $39.20M | $7.38M | -$33.29M | $34.91M | $24.81M | $20.13M | $15.61M | $21.23M | $9.18M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $21.33M | $25.99M | $15.11M | $23.40M | $30.61M | $38.08M | $38.58M | $43.08M | $48.88M | $53.19M | $8.00M | $9.97M |
| Total liabilities | $3.97M | $3.03M | $4.50M | $5.18M | $4.60M | $4.64M | $3.94M | $3.88M | $3.25M | $3.21M | $2.66M | $2.60M |
| Cash and equivalents | $6.06M | $22.46M | $7.94M | $8.24M | $9.44M | $8.32M | $10.50M | $9.00M | $7.74M | $10.01M | $6.37M | $7.79M |
| Shareholder equity | $17.36M | $22.96M | $10.62M | $18.22M | $26.01M | $33.44M | $34.63M | $39.20M | $45.64M | $49.98M | $5.34M | $7.38M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.45M | -$16.53M | -$7.45M | -$2.57M | -$14.50M | -$13.55M | -$9.86M | -$10.77M | -$12.33M | -$10.77M |
| Capital expenditures | $0 | $3 | $3 | $1 | $0 | $0 | $0 | $0 | $447.82K | $2.33K |
| Free cash flow | -$23.45M | -$16.53M | -$7.45M | -$2.57M | -$14.50M | -$13.55M | -$9.86M | -$10.77M | -$12.78M | -$10.77M |
| Share repurchases | N/A | N/A | $1.55M | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | $18.10M | -$28.66M | $0 | $0 | $4.00K | $0 | $0 | $0 | -$447.82K | $8.50M |
| Financing cash flow | $4.59M | $46.40M | $11.15M | $0 | $33.30M | $17.89M | $16.04M | $9.87M | $20.12M | $1.83M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.07M | -$6.92M | -$8.02M | -$6.58M | -$6.47M | -$6.51M | -$3.89M | -$8.05M | -$4.85M | -$2.20M | -$1.42M | -$2.54M |
| Capital expenditures | N/A | N/A | $0 | $0 | $0 | $5 | $0 | $0 | $0 | $5 | $0 | $4 |
| Free cash flow | N/A | N/A | -$8.02M | -$6.58M | -$6.47M | -$6.51M | -$3.89M | -$8.05M | -$4.85M | -$2.20M | -$1.42M | -$2.54M |
Frequently Asked Questions About CRVO
What is CervoMed's annual revenue?
CervoMed reported revenue of $4.01M for the fiscal year ended Dec 31, 2025.
How fast is CervoMed's revenue growing?
Revenue was down 58.9% for the fiscal year ended Dec 31, 2025 compared with the year before.
Is CervoMed profitable?
No. CervoMed reported net income of -$26.97M for the fiscal year ended Dec 31, 2025, with a net margin of -673.1%.
How much free cash flow does CRVO generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$23.45M minus capital expenditures of $0 produced free cash flow of -$23.45M.
How much debt does CervoMed have?
The balance sheet dated Dec 31, 2025 reported cash and equivalents of $8.24M.
CRVO pages: Overview, Earnings, Forecast, Financials, Competitors